Amyotrophic Lateral Sclerosis 1 (NIPA1)


Dred_IDRD00016
OMIM ID105400
Disease nameAmyotrophic Lateral Sclerosis 1
Alternative namesALS1, ALS
CategoryGenetic diseases, Rare diseases
PhenotypeOMIM: Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. ALS usually begins with asymmetric involvement of the muscles in middle adult life. Approximately 10% of ALS cases are familial (Siddique and Deng, 1996). ALS is sometimes referred to as 'Lou Gehrig disease' after the famous American baseball player who was diagnosed with the disorder. Rowland and Shneider (2001) and Kunst (2004) provided extensive reviews of ALS. Some forms of ALS occur with frontotemporal dementia (FTD); see 105500. Ranganathan et al. (2020) provided a detailed review of the genes involved in different forms of ALS with FTD, noting that common disease pathways involve disturbances in RNA processing, autophagy, the ubiquitin proteasome system, the unfolded protein response, and intracellular trafficking. The current understanding of ALS and FTD is that some forms of these disorders represent a spectrum of disease with converging mechanisms of neurodegenerastaion. Familial ALS is distinct from a form of ALS with dementia reported in cases on Guam (105500) (Espinosa et al., 1962; Husquinet and Franck, 1980), in which the histology is different and dementia and parkinsonism complicate the clinical picture. UniProtKB/Swiss-Prot 71 Amyotrophic lateral sclerosis 1: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.
Miscellaneousegenetic heterogeneity approximately 10% of als cases are familial
PrevalenceAmyotrophic Lateral Sclerosis: 1-9/100000 (Europe),1-9/100000 (United Kingdom),1-9/100000 (Ireland),1-9/100000 (Finland),1-9/100000 (Canada),1-9/100000 (United States),1-9/100000 (Uruguay),1-9/100000 (Denmark),1-9/100000 (Italy),1-9/100000 (France),1-9/100000 (Spain),1-9/100000 (Norway),1-9/1000000 (Taiwan, Province of China),1-9/100000 (Taiwan, Province of China),1-9/100000 (Faroe Islands),1-9/1000000 (Iran, Islamic Republic of),1-9/100000 (Iran, Islamic Republic of),1-9/100000 (Specific population),1-5/10000 (Specific population) [source: MalaCards]
InheritanceAutosomal recessive autosomal dominant
AnticipationYes
EvidenceWeak
Gene symbolNIPA1
Alias symbolsFSP3; SPG6; SLC57A1
Gene nameNIPA magnesium transporter 1
Gene map locus15q11.2; chr15:22,773,063-22,829,789(+)
Ensembl Gene IDENSG00000170113
Gene expression and Gene OntologyBioGPS
Protein expressionHuman Protein Atlas
Gene sequenceSequence
VariationClinVar,  dbSNP
Gene conservationGene Conservation from UCSC Genome Browser
Gene DescriptionThis gene encodes a magnesium transporter that associates with early endosomes and the cell surface in a variety of neuronal and epithelial cells. This protein may play a role in nervous system development and maintenance. Multiple transcript variants encoding different isoforms have been found for this gene. Mutations in this gene have been associated with autosomal dominant spastic paraplegia 6.
Repeat unitGCG
Normal repeat copies7-8
Pathogenic repeat copies≥9
GeneNIPA1
Repeat locationCDS
Chromosome locuschr15:22786678-22786703 (+)
Repeat conservationRepeat Conservation from UCSC Genome Browser
Toxic causeProtein
Possible toxicityNIPA1 (nonimprinted in Prader-Willi/Angelman syndrome 1) mutations are known to cause hereditary spastic paraplegia type 6, a neurodegenerative disease that phenotypically overlaps to some extent with amyotrophic lateral sclerosis (ALS). Previously, a genomewide screen for copy number variants found an association with rare deletions in NIPA1 and ALS, and subsequent genetic analyses revealed that long (or expanded) polyalanine repeats in NIPA1 convey increased ALS susceptibility. We set out to perform a large-scale replication study to further investigate the role of NIPA1 polyalanine expansions with ALS, in which we characterized NIPA1 repeat size in an independent international cohort of 3955 patients with ALS and 2276 unaffected controls and combined our results with previous reports. Meta-analysis on a total of 6245 patients with ALS and 5051 controls showed an overall increased risk of ALS in those with expanded (>8) GCG repeat length (odds ratio = 1.50, p = 3.8×10-5). Together with previous reports, these findings provide evidence for an association of an expanded polyalanine repeat in NIPA1 and ALS.
Pathway annotationReactome, KEGG
PMID30342764
AuthorsGijs H P Tazelaar, Annelot M Dekker, Joke J F A van Vugt, Rick A van der Spek, Henk-Jan Westeneng, Lindy J B G Kool, et al.
TitleAssociation of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort
JournalNeurobiology of Aging
Year2019
PMID22378146
AuthorsHylke M Blauw et al.
TitleNIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis
JournalHum Mol Genet.
Year2012


© 2024 Database of repeat expansion diseases.
Data collected by OmicsLab, IGDB, CAS. All rights reserved.